IP Library › Granted Patent US 12,466,893
Granted Patent B2
US 12,466,893 · App. 17/863,174 · Granted Nov 11, 2025

Antigen binding proteins

Inventors: Paul Algate (Issaquah, WA); Stephanie Jane Clegg (Stevenage, GB); Jennifer L. Craigen (Stevenage, GB); Paul Andrew Hamblin (Stevenage, GB); Alan Peter Lewis (Stevenage, GB); Patrick Mayes (Devon, PA); Radha Shah Parmar (Stevenage, GB); Trevor Anthony Kenneth Wattam (Stevenage, GB)
Assignee: Glaxo Group Limited
C07K16/3061A61K38/05A61K47/68031A61K47/6849C07K16/2803C07K16/2878A61K2039/505C07K2317/24C07K2317/33C07K2317/41C07K2317/56C07K2317/73C07K2317/732C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,893
App. No.
17/863,174
Granted
Nov 11, 2025
Kind
B2
Abstract

The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Claims (34)

1 . A method of treating a human patient afflicted with a B-cell maturation antigen (BCMA)-expressing B-cell lymphoma comprising:

administering to said human a dose of an immunoconjugate comprising an antibody and a cytotoxic agent,

wherein said antibody comprises a heavy chain variable region set forth in SEQ ID NO: 23 and a light chain variable region set forth in SEQ ID NO: 31, and

wherein said dose is in the range of about 1 mg/kg to about 5 mg/kg.

2 . The method of claim 1 , wherein the dose is administered once every 3 weeks.

3 . The method of claim 1 , wherein the cytotoxic agent is one selected from the group consisting of a calicheamicin, a maytansinoid, a dolastatin, an auristatin, a trichothecene, a DNA minor groove binding agent, a DNA minor groove alkylating agent, an enediyne, a lexitropsin, a duocarmycin, a taxane, a puromycin, a vinca alkaloid, an anti-tubulin agent, a podophyllotoxin, a baccatin derivative, a cryptophycin, and a combretastatin.

4 . The method of claim 1 , wherein the cytotoxic agent is an auristatin or a dolastatin.

5 . The method of claim 1 , wherein the cytotoxic agent is selected from monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF).

6 . The method of claim 1 , wherein the cytotoxic agent is covalently bound to said antibody.

7 . The method of claim 1 , wherein the antibody is linked to the cytotoxic agent via a linker.

8 . The method of claim 7 , wherein said linker is a cleavable linker.

9 . The method of claim 7 , wherein said linker is a non-cleavable linker.

10 . The method of claim 7 , wherein the linker is selected from 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-succinimidyl 4-(2-pyridylthio)pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate (SMCC), and N-succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

11 . The method of claim 7 , wherein the linker is 6-maleimidocaproyl (MC) and the cytotoxic agent is monomethyl auristatin F (MMAF).

12 . The method of claim 11 , wherein the antibody is afucosylated.

13 . The method of claim 11 , wherein the antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 55 and the light chain amino acid sequence of SEQ ID NO: 63.

14 . The method of claim 13 , wherein the antibody is afucosylated.

15 . The method of claim 1 , wherein the BCMA-expressing B-cell lymphoma is selected from: multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).

16 . The method of claim 1 , wherein the BCMA-expressing B-cell lymphoma is multiple myeloma (MM).

17 . The method of claim 16 , wherein the patient has newly diagnosed MM.

18 . The method of claim 16 , wherein the patient has relapsed MM.

19 . The method of claim 16 , wherein the patient has MM that is in remission.

20 . The method of claim 16 , wherein the patient is a MM patient that has progressive disease.

21 . The method of claim 11 , wherein the BCMA-expressing B-cell lymphoma is selected from: multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).

22 . The method of claim 12 , wherein the BCMA-expressing B-cell lymphoma is multiple myeloma (MM).

23 . The method of claim 22 , wherein the patient has newly diagnosed MM.

24 . The method of claim 22 , wherein the patient has relapsed MM.

25 . The method of claim 22 , wherein the patient has MM that is in remission.

26 . The method of claim 22 , wherein the patient is a MM patient that has progressive disease.

27 . The method of claim 14 , wherein the BCMA-expressing B-cell lymphoma is multiple myeloma (MM).

28 . The method of claim 27 , wherein the patient has newly diagnosed MM.

29 . The method of claim 27 , wherein the patient has relapsed MM.

30 . The method of claim 27 , wherein the patient has MM that is in remission.

31 . The method of claim 27 , wherein the patient is a MM patient that has progressive disease.

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXO GROUP LIMITED
To: GLAXO GROUP LIMITED
Reel/Frame 071044/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2022
From: ALGATE, PAUL; CLEGG, STEPHANIE JANE; CRAIGEN, JENNIFER L.; HAMBLIN, PAUL ANDREW; LEWIS, ALAN PETER; MAYES, PATRICK; PARMAR, RADHA SHAH; WATTAM, TREVOR ANTHONY KENNETH
To: GLAXO GROUP LIMITED
Reel/Frame 060494/0134 →
Continuity (7)
Division 16815677 · Mar 11, 2020
Continuation 15828770 · Dec 1, 2017
Continuation 14974675 · Dec 18, 2015
Continuation 13795314 · Mar 12, 2013
Continuation PCTEP2012059762 · May 24, 2012
Provisional Application 61490732 · May 27, 2011
Related Publication 20230137032A1 · May 4, 2023
References Cited (80)
US 5635483A · Pettit et al. · 1997 [cited by applicant]
US 5968753A · Tseng-Law et al. · 1999 [cited by applicant]
US 6214345B1 · Firestone et al. · 2001 [cited by applicant]
US 6884869B2 · Senter et al. · 2005 [cited by applicant]
US 6962702B2 · Hansen et al. · 2005 [cited by applicant]
US 7083785B2 · Browning et al. · 2006 [cited by applicant]
US 7091186B2 · Senter et al. · 2006 [cited by applicant]
US 7498298B2 · Doronina et al. · 2009 [cited by applicant]
US 7553816B2 · Senter et al. · 2009 [cited by applicant]
US 7659241B2 · Senter et al. · 2010 [cited by applicant]
US 7745394B2 · Doronina et al. · 2010 [cited by applicant]
US 7750116B1 · Doronina et al. · 2010 [cited by applicant]
US 7829531B2 · Senter et al. · 2010 [cited by applicant]
US 7837980B2 · Alley et al. · 2010 [cited by applicant]
US 7851437B2 · Senter et al. · 2010 [cited by applicant]
US 7964566B2 · Doronina et al. · 2011 [cited by applicant]
US 7964567B2 · Doronina et al. · 2011 [cited by applicant]
US 7994135B2 · Doronina et al. · 2011 [cited by applicant]
US 8039273B2 · Jeffrey · 2011 [cited by applicant]
US 8163551B2 · Alley et al. · 2012 [cited by applicant]
US 8288352B2 · Doronina et al. · 2012 [cited by applicant]
US 8343928B2 · Doronina et al. · 2013 [cited by applicant]
US 8455622B2 · McDonagh et al. · 2013 [cited by applicant]
US 8512707B2 · Doronina et al. · 2013 [cited by applicant]
US 8557780B2 · Doronina et al. · 2013 [cited by applicant]
US 8568728B2 · Jeffrey · 2013 [cited by applicant]
US 8574907B2 · Alley et al. · 2013 [cited by applicant]
US 9273141B2 · Algate et al. · 2016 [cited by applicant]
US 20020028178A1 · Hanna et al. · 2002 [cited by applicant]
US 20030054497A1 · Co et al. · 2003 [cited by applicant]
US 20030105000A1 · Pero et al. · 2003 [cited by applicant]
US 20090220502A1 · Brandt et al. · 2009 [cited by applicant]
US 20090226434A1 · Auer et al. · 2009 [cited by applicant]
US 20100021474A1 · Kirchhofer et al. · 2010 [cited by applicant]
US 20100267932A1 · Eon-Duval et al. · 2010 [cited by applicant]
US 20130280280A1 · Algate et al. · 2013 [cited by applicant]
US 20140105915A1 · Algate et al. · 2014 [cited by applicant]
US 20160193358A1 · Algate et al. · 2016 [cited by applicant]
US 20220411512A1 · Hoos et al. · 2022 [cited by applicant]
WO 0040716A2 · 2000 [cited by applicant]
WO 0112812A2 · 2001 [cited by applicant]
WO 0124811A1 · 2001 [cited by applicant]
WO 0160397A1 · 2001 [cited by applicant]
WO 2002066516A2 · 2002 [cited by applicant]
WO 03072713A2 · 2003 [cited by applicant]
WO 2005075511A1 · 2005 [cited by applicant]
WO 2006067210A1 · 2006 [cited by applicant]
WO 2010104949A2 · 2010 [cited by applicant]
WO 2011042548A1 · 2011 [cited by applicant]
WO 2011108008A2 · 2011 [cited by applicant]
WO 2012066058A1 · 2012 [cited by applicant]
WO 2012163805A1 · 2012 [cited by applicant]
Dogan et al (Blood cancer Journal 10:73 2020 (Year: 2020). [cited by examiner]
Abcam, “KD value: A quantitative measurement of antibody affinity”, 8 pages (2017). [cited by applicant]
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single… [cited by applicant]
Cai et al., “DNA minor groove binders: Back in the groove”, Cancer Treatment Reviews, vol. 35, pp. 437-450 (2009). [cited by applicant]
Carter et al., “Antibody-Drug Conjugates for Cancer Therapy”, Cancer Journal, vol. 14, No. 3, pp. 154-169 (2008). [cited by applicant]
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design”, Biochemical and Biophysical Research Communications, vol. 307, pp. 198-205 (2003). [cited by applicant]
Claudio et al., “A molecular compendium of genes expressed in multiple myeloma,” Blood, vol. 100, No. 6, pp. 2175-2186, (2002). [cited by applicant]
Colman P.M., “Effects of amino acid sequence changes on antibody-antigen interactions Original”, Research in Immunology, vol. 145, Issue 1, pp. 33-36 (1994). [cited by applicant]
Doronina et al., “Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity”, Bioconjugate Chemistry, vol. 17, Issue 1, pp. 114-124 (2006). [cited by applicant]
Güssow et al., “Humanization of monoclonal antibodies”, Methods in Enzymology, vol. 203, pp. 99-121 (1991). [cited by applicant]
Hudson et al., “Engineered antibodies”, Nature Medicine, vol. 9, pp. 129-134 (2003). [cited by applicant]
Ibragimova, et al., “Stability of the β-Sheet of the WW Domain: A Molecular Dynamics Simulation Study”, Biophysical Journal, vol. 77, Issue 4, pp. 2191-2198 (1999). [cited by applicant]
Jefferis et al., “Interaction sites on human IgG-Fc for FcγR: current models”, Immunology Letters, vol. 82, Issues 1-2, pp. 57-65 (2002). [cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function”, PNAS, vol. 103, No. 11, pp. 4005-4010 (2006). [cited by applicant]
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography”, Journal of Molecular Biology, vol. 262, Issue 5, pp. 732-745 (1996). [cited by applicant]
Mori et al., “Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies”, Cytotechnology, vol. 55, Issue 2, pp. 109-114 (2007). [cited by applicant]
PB64476T OA U.S. Appl. No. 13/795,314 Final Rejection dated Apr. 14, 2015. [cited by applicant]
Peters et al., “Antibody-drug conjugates as novel anti-cancer chemotherapeutics,” Bioscience Reports, vol. 35, e00225, doi:10.1042/BSR20150089 (2015). [cited by applicant]
Polson et al., “Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection”, Cancer Res., vol. 69, No. 6, pp. 2358-2364, DOI: 10.1158/0008-5472.CAN-08-2250 (2009), Correction,… [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proceedings of the National Academy of Sciences, vol. 79, No. 6, pp. 1979-1983 (1982). [cited by applicant]
Ryan et al., “Antibody targeting of B-cell maturation antigen on malignant plasma cells”, Mol. Cancer Ther., vol. 6, No. 11, pp. 3009-3018 (2007). [cited by applicant]
Shadidi et al., “An Anti-leukemic Single Chain Fv Antibody Selected from a Synthetic Human Phage Antibody Library”, BBRC, vol. 280, pp. 548-552 (2001). [cited by applicant]
Shu et al., “B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1”, Proceedings of the National Academy of Sciences, vol. 97, No. 16, pp. 9156-9161 (2000). [cited by applicant]
Yamane-Ohnuki et al., “Establishment of FUT8 Knockout Chinese Hamster Ovary Cells: An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies with Enhanced Antibody-Dependent Cellular Cytotoxicity”, Biote… [cited by applicant]
Yang et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range”, J. Mol. Biol., vol. 254, pp. 392-403 (1995). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2012/059762, mailed Aug. 31, 2012, 13 Pages. [cited by applicant]
Janeway C.A., et al., The Interaction of the Antibody Molecules with Sepcific Antigen, Immuno Biology 5, 2001, pp. 100-101 (4 Pages). [cited by applicant]
“NCI-H929 [H929] ATCC CRL-9068,” [cited by applicant]